Benjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.
Benjamin H. Lowentritt, MD, FACS
Benjamin H. Lowentritt, MD, FACS, is the medical director of prostate cancer and a practicing urologist at Chesapeake Urology in Baltimore, MD.
Articles by Benjamin H. Lowentritt, MD, FACS